Drug-susceptible tuberculosis treatment cost data are available from the perspective of both providers and patients from various settings around the world.

Multidrug-resistant tuberculosis treatment costs are not widely available, particularly not for middle- and low-income countries.

Productivity losses were presented in 57 % of the papers, for both drug-susceptible and multidrug-resistant tuberculosis. However, methods used varied widely, reflecting the lack of clear guidelines on the best instrument and methods for this estimation.